Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 12, 2017, Pages E2337-E2346

  Bierie, Brian ^a   Pierce, Sarah E ^b   Kroeger, Cornelia ^a   Stover, Daniel G ^c   Pattabiraman, Diwakar R ^a   Thiru, Prathapan ^a   Donaher, Joana Liu ^a   Reinhardt, Ferenc ^a   Chaffer, Christine L ^a   Keckesova, Zuzana ^a   Weinberg, Robert A ^a,d  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BROWN UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; EMT; Heterogeneity; ITGB4; Mesenchymal

Indexed keywords

BETA4 INTEGRIN; PROTEIN; TRANSCRIPTION FACTOR ZEB1; TUMOR PROTEIN 63 ISOFORM 1; UNCLASSIFIED DRUG; ITGB4 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CARCINOMA CELL; CELL POPULATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MESENCHYMAL CARCINOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; CARCINOMA; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; MESODERM; METABOLISM; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

CARCINOMA; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INTEGRIN BETA4; MESODERM; NEOPLASTIC STEM CELLS; PROGNOSIS; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85016103373     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1618298114     Document Type: Article

References (48)

1. Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) Emt: 2016. Cell 166(1):21-45.
2. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415-428.
3. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983-3988.
5. Pattabiraman DR, Weinberg RA (2014) Tackling the cancer stem cells: What challenges do they pose? Nat Rev Drug Discov 13(7):497-512.
6. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15(3):178-196.
7. Zadran S, Arumugam R, Herschman H, Phelps ME, Levine RD (2014) Surprisal analysis characterizes the free energy time course of cancer cells undergoing epithelial-tomesenchymal transition. Proc Natl Acad Sci USA 111(36):13235-13240.
8. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 172(7):973-981.
9. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704-715.
10. Medema JP (2013) Cancer stem cells: The challenges ahead. Nat Cell Biol 15(4): 338-344.
11. Vivanco MdM (2015) Mammary Stem Cells: Methods and Protocols (Humana Press, New York), pp x, 275 pp.
12. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2- negative invasive breast cancer, the so-called triple-negative phenotype: A population- based study from the California cancer Registry. Cancer 109(9):1721-1728.
13. Stewart RL, O'Connor KL (2015) Clinical significance of the integrin α6β4 in human malignancies. Lab Invest 95(9):976-986.
14. Leng C, et al. (2016) An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAKAKT pathway. Cancer Lett 376(1):188-196.
15. Bertotti A, Comoglio PM, Trusolino L (2006) Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol 175(6):993-1003.
16. Lu S, Simin K, Khan A, Mercurio AM (2008) Analysis of integrin beta4 expression in human breast cancer: Association with basal-like tumors and prognostic significance. Clin Cancer Res 14(4):1050-1058.
17. Masugi Y, et al. (2015) Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Lab Invest 95(3):308-319.
18. Stewart RL, et al. (2016) Elevated integrin α6β4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer. Hum Pathol 54: 174-183.
19. Lehmann BD, et al. (2016) Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One 11(6): e0157368.
20. Lehmann BD, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750-2767.
21. Elenbaas B, et al. (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15(1):50-65.
22. Tam WL, et al. (2013) Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24(3):347-364.
23. Morel AP, et al. (2008) Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoS One 3(8):e2888.
24. Jolly MK, et al. (2015) Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol 5:155.
25. Guo W, et al. (2012) Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148(5):1015-1028.
26. Ye X, et al. (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525(7568):256-260.
27. Nielsen TO, et al. (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 16(21):5222-5232.
28. Parker JS, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167.
29. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486(7403):346-352.
30. Györffy B, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat 123(3):725-731.
31. Carroll DK, et al. (2006) p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 8(6):551-561.
32. Drake JM, et al. (2010) ZEB1 coordinately regulates laminin-332 and beta4 integrin expression altering the invasive phenotype of prostate cancer cells. J Biol Chem 285(44):33940-33948.
33. Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H (2016) Tumor budding: The name is EMT. Partial EMT. J Clin Med 5(5):E51.
34. Jolly MK, et al. (2016) Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 7(19):27067-27084.
35. Taube JH, et al. (2010) Core epithelial-to-mesenchymal transition interactome geneexpression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107(35):15449-15454.
36. Pattabiraman DR, et al. (2016) Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science 351(6277):aad3680.
37. Chang C, Yang X, Pursell B, Mercurio AM (2013) Id2 complexes with the SNAG domain of Snai1 inhibiting Snai1-mediated repression of integrin β4. Mol Cell Biol 33(19): 3795-3804.
38. Turner FE, et al. (2006) Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes. J Biol Chem 281(30):21321-21331.
39. Ginestier C, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555-567.
40. Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11(8):783-784.
41. Hu Y, Smyth GK (2009) ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347(1-2):70-78.
42. Kim D, et al. (2013) TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14(4):R36.
43. Anders S, Pyl PT, Huber W (2015) HTSeq: A Python framework to work with highthroughput sequencing data. Bioinformatics 31(2):166-169.
44. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550.
45. de Hoon MJ, Imoto S, Nolan J, Miyano S (2004) Open source clustering software. Bioinformatics 20(9):1453-1454.
46. Saldanha AJ (2004) Java Treeview: Extensible visualization of microarray data. Bioinformatics 20(17):3246-3248.
47. Lappalainen I, et al. (2015) The European Genome-Phenome Archive of human data consented for biomedical research. Nat Genet 47(7):692-695.
48. Basu A, et al. (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154(5):1151-1161.